Medicine Recommendations

Rheumatoid arthritis (LSCMMG pathway)

Ankylosing spondylitis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Crohn's disease

Non-radiographic axial spondyloarthritis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Certolizumab pegol for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)

NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

NICE TA574 - Certolizumab pegol for treating moderate to severe plaque psoriasis

Ulcerative Colitis

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Alcohol withdrawal

Anxiety

Schizophrenia and other psychoses, mania, anxiety, agitation, violent or dangerously impulsive behaviour, childhood schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia and other psychoses, mania, anxiety, agitation, violent or dangerously impulsive behaviour, childhood schizophrenia

Severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.

Severe acute ulcerative colitis

Rheumatic diseases, dermatology and severe ulcerative colitis

Dry eye disease that has not improved despite treatment with artificial tears (NICE TA369)

NICE TA369 - Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears

Peripheral arterial disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 

Premature ejaculation

MHRA Drug Safety Update - Citalopram and escitalopram: QT interval prolongation

Depressive illness, panic disorder

MHRA Drug Safety Update - Citalopram and escitalopram: QT interval prolongation

Adjunct in epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products